Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies L Amiri-Kordestani, A Basseville, K Kurdziel, AT Fojo, SE Bates Drug Resistance Updates 15 (1-2), 50-61, 2012 | 268 | 2012 |
Histone deacetylase inhibitors: emerging mechanisms of resistance RW Robey, AR Chakraborty, A Basseville, V Luchenko, J Bahr, Z Zhan, ... Molecular pharmaceutics 8 (6), 2021-2031, 2011 | 142 | 2011 |
Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells A Basseville, L Preisser, S de Carné Trécesson, M Boisdron-Celle, ... Molecular cancer 10, 1-12, 2011 | 61 | 2011 |
Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter A Basseville, A Tamaki, C Ierano, S Trostel, Y Ward, RW Robey, ... Cancer research 72 (14), 3642-3651, 2012 | 54 | 2012 |
BCL-XL directly modulates RAS signalling to favour cancer cell stemness S Carné Trécesson, F Souazé, A Basseville, AC Bernard, J Pécot, ... Nature Communications 8 (1), 1123, 2017 | 42 | 2017 |
Gout, genetics and ABC transporters A Basseville, SE Bates F1000 biology reports 3, 2011 | 39 | 2011 |
Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model OK Serrano, NL Parrow, PC Violet, J Yang, J Zornjak, A Basseville, ... Free Radical Biology and Medicine 87, 193-203, 2015 | 38 | 2015 |
The ABCG2 multidrug transporter A Basseville, MD Hall, CH Chau, RW Robey, M Gottesman, WD Figg, ... ABC transporters-40 years on, 195-226, 2016 | 23 | 2016 |
Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras JC Bahr, RW Robey, V Luchenko, A Basseville, AR Chakraborty, ... Oncotarget 7 (43), 69804, 2016 | 17 | 2016 |
Histone deacetylase inhibitors induce CXCR4 mRNA but antagonize CXCR4 migration C Ierano, A Basseville, KKW To, Z Zhan, RW Robey, J Wilkerson, ... Cancer Biology & Therapy 14 (2), 175-183, 2013 | 15 | 2013 |
R-loop–mediated ssDNA breaks accumulate following short-term exposure to the HDAC inhibitor romidepsin M Safari, T Litman, RW Robey, A Aguilera, AR Chakraborty, WC Reinhold, ... Molecular Cancer Research 19 (8), 1361-1374, 2021 | 12 | 2021 |
ABC transporters-40 years on A Basseville, MD Hall, CH Chau, RW Robey, M Gottesman, WD Figg, ... Springer International Publishing, Cham, 2016 | 7 | 2016 |
Targeting KRAS and the vitamin D receptor via microtubules A Basseville, S Bates, T Fojo Nature Reviews Clinical Oncology 12 (8), 442-444, 2015 | 6 | 2015 |
Breast cancer resistance protein (BCRP) or ABCG2 A Basseville, RW Robey, JC Bahr, SE Bates Drug transporters: molecular characterization and role in drug disposition …, 2014 | 6 | 2014 |
BCRP (ABCG2) A Basseville, SE Bates, WD Figg, A Sparreboom Pharmacogenomics of human drug transporters: Clinical impacts, 311-343, 2013 | 6 | 2013 |
Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties TL Bonneaud, CC Lefebvre, L Nocquet, A Basseville, J Roul, H Weber, ... Cell death & disease 13 (9), 787, 2022 | 4 | 2022 |
A histone deacetylase inhibitor induces acetyl-coA depletion leading to lethal metabolic stress in RAS-pathway activated cells A Basseville, PC Violet, M Safari, C Sourbier, WM Linehan, RW Robey, ... Cancers 14 (11), 2643, 2022 | 3 | 2022 |
Brain neural progenitors are new predictive biomarkers for breast cancer hormonotherapy A Basseville, C Cordier, F Ben Azzouz, W Gouraud, H Lasla, F Panloup, ... Cancer Research Communications 2 (8), 857-869, 2022 | 1 | 2022 |
Interest of the bc-GenExMiner web tool in oncology P Jezequel, W Gouraud, FB Azzouz, A Basseville, PP Juin, H Lasla, ... Bulletin du Cancer 108 (11), 1057-1064, 2021 | 1 | 2021 |
Characterization of the aggresome targeted Q141K ABCG2/BCRP variant. A Basseville, S Shukla, A Tamaki, R Robey, SV Ambudkar, SE Bates Cancer Research 73 (8_Supplement), 2193-2193, 2013 | 1 | 2013 |